immunotherapy

Aging promotes reactivation from metastatic melanoma dormancy

How does the primary tumor imprint a dormancy signature in disseminated tumor cells?

T cells specific for alpha-myosin drive immunotherapy-related myocarditis

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

When to stop immune checkpoint inhibitor for malignant melanoma? Challenges in emulating target trials

Observational data have become a popular source of evidence for causal effects when no randomized controlled trial exists, or to supplement information provided by those. In practice, a wide range of designs and analytical choices exist, and one recent approach relies on the target trial emulation framework. This framework is particularly well suited to mimic what could be obtained in a specific randomized controlled trial, while avoiding time-related selection biases. In this abstract, we present how this framework could be useful to emulate trials in malignant melanoma, and the challenges faced when planning such a study using longitudinal observational data from a cohort study. More specifically, two questions are envisaged: duration of immune checkpoint inhibitors, and trials comparing treatment strategies for BRAF V600-mutant patients (targeted therapy as 1st line, followed by immunotherapy as 2nd line, vs. immunotherapy as 2nd line followed by targeted therapy as 1st line). Using data from 1027 participants to the MELBASE cohort, we detail the results for the emulation of a trial where immune checkpoint inhibitor would be stopped at 6 months vs. continued, in patients in response or with stable disease.

Novel immunotherapy to treat Alzheimer’s disease and Dementia: from curiosity-driven research to prospect of therapy

Anti-PD1 immunotherapy exacerbates cognitive deficits induced by immunogenic cancer in mice

Co-Targeting Tumor Microenvironment-Instigated Adaptation To Hypoxia Renders Glioblastoma More Susceptible To Oncolytic Virus Immunotherapy

Nanobody-based immunotherapy for depression

FENS Forum 2024

In vitro and in vivo targeting of amyloid-beta oligomers through intrabodies: Towards an innovative gene immunotherapy for Alzheimer’s disease

FENS Forum 2024